

Zydus Cadila Net Profit up by 82% in Q3

Ahmedabad, February 7, 2014

For the third quarter ended 31st December 2013, Cadila Healthcare Limited registered a Net Profit of Rs. 186 crores, up by 82% from Rs. 102 crores in the corresponding period last year. The company registered a Total Income of Rs. 1,872 crores up by 17% from Rs. 1,604 crores in the corresponding period last year, on a consolidated basis.

During the quarter, the company's business in the US registered a growth of 61% and Emerging Markets business grew by 30%.

During the quarter, the company filed 31 additional ANDAs with the US FDA taking the cumulative ANDA filings for the period April-December 2013, to 49. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to 6 and filed 8 dossiers with the Mexican regulatory authority, taking the cumulative filings to 36. The company filed 9 dossiers with the ANVISA, taking the cumulative filings to 113. In the European market, the company received the approval for 15 new product dossiers and launched 2 new products in France and 3 new products in Spain. 7 new products were launched in the different Emerging Markets during the quarter.

During the quarter, the company received the US FDA approval for initiating Phase I clinical trials of ZYDPLA1 – a novel, next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes.

For Biosimilars, the company initiated Phase III clinical trials for one of the mAbs and completed Phase I clinical trials completed for both the novel biologics, PEGEPO and Rabimabs.
